Table 2.
Clinicopathological and biochemical factors influencing 3-year disease-free survival and 3-year overall survival of melanoma patients
| Patient characteristics | 3-year DFS (%) | p value | 3-year OS (%) | p value |
|---|---|---|---|---|
| Gender | ||||
| Female | 76.3 | 0.040 | 86.6 | 0.103 |
| Male | 67.0 | 83.9 | ||
| Age at the time of the diagnosis | ||||
| ≤55 years | 75.7 | 0.310 | 87.1 | 0.664 |
| >55 years | 67.0 | 83.2 | ||
| Anatomic site of primary tumor | ||||
| Trunk | 74.8 | 0.992 | 92.2 | 0.789 |
| Upper extremity | 72.7 | 79.7 | ||
| Lower extremity | 69.9 | 84.8 | ||
| Other | 64.8 | 64.8 | ||
| Ulceration | ||||
| Yes | 84.1 | 0.003 | 94.9 | 0.002 |
| No | 60.8 | 76.4 | ||
| Breslow scale | ||||
| pT1 | 89.8 | <0.001 | 96.6 | 0.012 |
| pT2 | 72.4 | 89.3 | ||
| pT3 | 71.1 | 83.5 | ||
| pT4 | 52.1 | 70.4 | ||
| Lymph node status | ||||
| pN0 | 80.8 | <0.001 | 93.2 | <0.001 |
| pN1 | 66.2 | 82.9 | ||
| pN2 | 44.4 | 77.8 | ||
| pN3 | 22.2 | 29 | ||
| Clinical stage | ||||
| I | 87.2 | <0.001 | 97.8 | <0.001 |
| II | 74.0 | 88.3 | ||
| III | 51.4 | 68.1 | ||
| TIMP-1 | ||||
| ≤160 ng/ml (low) | 81.4 | 0.014 | 88.8 | 0.050 |
| >160 ng/ml (high) | 61.0 | 81.5 | ||
| YKL-40 | ||||
| ≤80 ng/ml (low) | 77.0 | 0.164 | 92.5 | 0.111 |
| >80 ng/ml (high) | 59.4 | 78.9 | ||
| VEGF | ||||
| ≤399 pg/ml (low) | 72.0 | 0.799 | 82.3 | 0.616 |
| >399 pg/ml (high) | 71.5 | 88.2 | ||
| MMP-9 | ||||
| ≤741 ng/ml (low) | 68.8 | 0.583 | 80.8 | 0.258 |
| >741 ng/ml (high) | 71.5 | 89.7 | ||